Moderna combined its vaccine with Merck's Keytruda drug.
3 reports, 2 independent
Updated Sep 4
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Moderna combined its vaccine with Merck's Keytruda drug.
Who's involved
What this event is mainly aboutKeep exploring
Part of
Moderna announced a collaboration with Merck KGaA regarding a personalized cancer vaccine platform.Also in this story
- Moderna and Merck KGaA are working on personalized melanoma shots, with manufacturing challenges being discussed by Amy Walker.
- Moderna and Merck developed personalized mRNA cancer vaccine Intismeran following trial success, leading to a surge in Moderna's shares.
- Moderna and Merck developed a new therapy.
- Moderna, Merck, and the National Cancer Institute announced successful trial results for a combined cancer vaccine and immunotherapy program.
The entities involved
Related events
- Moderna and Merck announced the successful outcome of their Phase 3 combined treatment trials involving a new cancer vaccine and Keytruda.
- On August 28, 2026, the FDA approved Moderna's mNEXSPIKE vaccine and gave the green light to Novavax's Nuvaxovid vaccine. Separately, ProFound Therapeutics was formed by Flagship Pioneering.
- Trump administration pushes vaccine approval while FDA moves forward with Moderna vaccine, with Fauci noting incomplete protection.
- North Carolina donated funds to support the development of Moderna's vaccine.